night traf7  (Proteintech)

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence

doi: 10.1186/s13046-025-03363-1

Figure Lengend Snippet: Clinicopathological parameters of Glioma in Xiangya Cohort

Article Snippet: The sections were maintained with primary antibodies at 4°C throughout the night: TRAF7 (1:300, 11,780–1-AP, Proteintech, China), Ki67 (1:400, #9449, CST, USA), P53 (1:200, #2527, CST, USA), P21 (1:100, #2947, CST, USA), CCND1 (1:200, ab134175, Abcam, UK), CDK2 (1:100, ab32147, Abcam, UK).

Techniques: Expressing

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence

doi: 10.1186/s13046-025-03363-1

Figure Lengend Snippet: High expression of TRAF7 is closely associated with poor prognosis in glioma. A The expression of TRAF7 mRNA was quantitatively analyzed between the glioma tumor site and normal brain tissues based on TCGA database. B - C Kaplan–Meier survival and ROC curves using TCGA. D - E Kaplan–Meier survival curves and ROC for predicting the 1-, 3- and 5-year overall survival ( p < 0.0001) in CCGA. F The Nomogram model was built to analyze prognostic factors in 1-, 3-, and 5-year OS of glioma patients. G Decision curve analysis (DCA) for the clinical benefits and application of the nomogram. H - J Calibration curves of the nomogram model for 1-year, 3-year, and 5-year OS. K TRAF7 expression were examined by qRT-PCR in six glioma cell lines. L The knockdown efficiency of TRAF7 mRNA in Hs683 and U251 cells. M The protein expression of TRAF7 was conducted by western blot. N – O TRAF7 protein expression was quantified in Hs683 and U251 cells. Data are presented as the mean ± SD

Article Snippet: The sections were maintained with primary antibodies at 4°C throughout the night: TRAF7 (1:300, 11,780–1-AP, Proteintech, China), Ki67 (1:400, #9449, CST, USA), P53 (1:200, #2527, CST, USA), P21 (1:100, #2947, CST, USA), CCND1 (1:200, ab134175, Abcam, UK), CDK2 (1:100, ab32147, Abcam, UK).

Techniques: Expressing, Quantitative RT-PCR, Knockdown, Western Blot

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence

doi: 10.1186/s13046-025-03363-1

Figure Lengend Snippet: The clinical characteristics of glioma patients. A Heat map of 143 glioma patients with clinical characteristics, including 76 recurrent samples. B - D The TRAF7 expression levels of glioma patients displayed differences in their pathological stages. E – F The representative images of Hematoxylin and IHC staining were shown in different TRAF7 expression groups (The scale bar for HE staining and 40 × IHC staining is 50 µm, and the scale bar for 20 × IHC staining is 100 µm). G - H Survival curves of RFS and OS glioma patients with varying levels of TRAF7 expression

Article Snippet: The sections were maintained with primary antibodies at 4°C throughout the night: TRAF7 (1:300, 11,780–1-AP, Proteintech, China), Ki67 (1:400, #9449, CST, USA), P53 (1:200, #2527, CST, USA), P21 (1:100, #2947, CST, USA), CCND1 (1:200, ab134175, Abcam, UK), CDK2 (1:100, ab32147, Abcam, UK).

Techniques: Expressing, Immunohistochemistry, Staining

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence

doi: 10.1186/s13046-025-03363-1

Figure Lengend Snippet: Univariate Cox regression of TRAF7 expression for overall survival in glioma patients

Article Snippet: The sections were maintained with primary antibodies at 4°C throughout the night: TRAF7 (1:300, 11,780–1-AP, Proteintech, China), Ki67 (1:400, #9449, CST, USA), P53 (1:200, #2527, CST, USA), P21 (1:100, #2947, CST, USA), CCND1 (1:200, ab134175, Abcam, UK), CDK2 (1:100, ab32147, Abcam, UK).

Techniques: Expressing

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence

doi: 10.1186/s13046-025-03363-1

Figure Lengend Snippet: The knockdown of TRAF7 inhibits cell proliferation and migration in vitro . A - B Transwell assays in Hs683 and U251 cells. C - D Colony formation assays visualized on day 14. E – F The Hs683 and U251 cell lines with TRAF7 knockdown significantly inhibited cell proliferation by EDU assays. G - I Wound healing assays and migration rate at 24 and 48 h. J - K Cell viability was determined by the CCK-8 assay. Data are presented as the mean ± SEM from three independent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001

Article Snippet: The sections were maintained with primary antibodies at 4°C throughout the night: TRAF7 (1:300, 11,780–1-AP, Proteintech, China), Ki67 (1:400, #9449, CST, USA), P53 (1:200, #2527, CST, USA), P21 (1:100, #2947, CST, USA), CCND1 (1:200, ab134175, Abcam, UK), CDK2 (1:100, ab32147, Abcam, UK).

Techniques: Knockdown, Migration, In Vitro, CCK-8 Assay

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence

doi: 10.1186/s13046-025-03363-1

Figure Lengend Snippet: TRAF7 loss sensitizes glioma to senescence and G0/G1 arrest by RNA sequencing. A Volcano plot of differentially expressed genes between the control group and siTRAF7 group in the Hs683 and U251 cells. B GSEA revealed the enrichment of differentially expressed genes. C The pathway enrichment analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG). D Heatmap of the differentially expressed (|log2FC|> 2 and p -value < 0.05) genes via RNA-seq. E The Hs683 and U251 cells with TRAF7 knockdown induced senescence. F Knockdown of TRAF7 induced G0/G1 arrest of Hs683 and U251 cells. G The heatmap of senescence and cell-cycle related genes. H - I mRNA expression of G0/G1 arrest related genes. J Protein expression of G0/G1 arrest related genes in Hs683 and U251 cells. K - L mRNA expression of senescence related genes in Hs683 and U251 cells. M – N The protein expression of G0/G1 arrest and senescence related genes

Article Snippet: The sections were maintained with primary antibodies at 4°C throughout the night: TRAF7 (1:300, 11,780–1-AP, Proteintech, China), Ki67 (1:400, #9449, CST, USA), P53 (1:200, #2527, CST, USA), P21 (1:100, #2947, CST, USA), CCND1 (1:200, ab134175, Abcam, UK), CDK2 (1:100, ab32147, Abcam, UK).

Techniques: RNA Sequencing, Control, Knockdown, Expressing

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence

doi: 10.1186/s13046-025-03363-1

Figure Lengend Snippet: Combination of Lomustine (CCNU) and sh-TRAF7 promotes glioma senescence and G0/G1 arrest. A IC50 of lomustine (CCNU). B Cell viability of TRAF7 deficient cell lines treated with low concentrations of lomustine (1 μM and 10 μM) for 12 h. C Cell viability of Hs683 and U251 cells treated with lomustine (50 μM). D SA-β-gal staining after CCNU treatment of the control group and sh-TRAF7 group in the cells. E – F The mRNA expression and protein expression of G0/G1 arrest related genes after CCNU treatment. G - H mRNA expression and protein expression of senescence related genes after CCNU treatment in the cells

Article Snippet: The sections were maintained with primary antibodies at 4°C throughout the night: TRAF7 (1:300, 11,780–1-AP, Proteintech, China), Ki67 (1:400, #9449, CST, USA), P53 (1:200, #2527, CST, USA), P21 (1:100, #2947, CST, USA), CCND1 (1:200, ab134175, Abcam, UK), CDK2 (1:100, ab32147, Abcam, UK).

Techniques: Staining, Control, Expressing

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence

doi: 10.1186/s13046-025-03363-1

Figure Lengend Snippet: TRAF7 depletion inhibits glioma proliferation and induces senescence via KLF4. A Kaplan–Meier survival using TCGA on KLF4. B The overexpression of KLF4 in Hs683 and U251 cells. C The expression of TRAF7 and KLF4 in the Hs683 and U251 glioma cell lines. D Co-immunoprecipitation (Co-IP) assays were performed using lysates from U251 cells transfected with Flag-tagged KLF4 and HA-tagged TRAF7. E – F Colony formation assays were performed in the glioma cell lines with or without KLF4 overexpression. G - H SA-β-gal staining was performed in the glioma cell lines (scale bar = 50 µm). I - J The rescue colony formation assay showed that the inhibitory effects of TRAF7 knockdown on cell proliferation could be rescued by additional KLF4 overexpression in cells. K - L The rescue SA-β-gal staining assay showed that the promotion effects of TRAF7 knockdown on cell senescence could be rescued by additional KLF4 overexpression in cells (scale bar = 50 µm). * p < 0.05, ** p < 0.01, and *** p < 0.001

Article Snippet: The sections were maintained with primary antibodies at 4°C throughout the night: TRAF7 (1:300, 11,780–1-AP, Proteintech, China), Ki67 (1:400, #9449, CST, USA), P53 (1:200, #2527, CST, USA), P21 (1:100, #2947, CST, USA), CCND1 (1:200, ab134175, Abcam, UK), CDK2 (1:100, ab32147, Abcam, UK).

Techniques: Over Expression, Expressing, Immunoprecipitation, Co-Immunoprecipitation Assay, Transfection, Staining, Colony Assay, Knockdown

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence

doi: 10.1186/s13046-025-03363-1

Figure Lengend Snippet: Establishment of patient-derived primary and recurrent glioma stem cell spheres (GSCs). A The expression of TRAF7 in primary and recurrent patient-derived glioma cells with or without knockdown. B IC50 of Lomustine (CCNU) in primary and recurrent glioma stem cells. C Cell viability of primary and recurrent patient-derived glioma cells treated with lomustine (50 μM). D Brightfield image of GSC spheres in Matrigel (scale bar = 100 µm). E The radar chart provides a comprehensive comparison of different cells, including the inhibitory efficiency of combined therapy, tumor sphere size, CD133 expression levels, and migration capacity. F Evaluation of the GSCs formation ability between the control group and si-TRAF7 group treated with or without CCNU (scale bar = 100 µm). G The primary and recurrent glioma stem cells were stained with stem cell markers (CD133) (scale bar = 100 µm). H Transwell assays of pGSC#3 and rGSC#1 (scale bar = 50 µm). I Heat map of three primary glioma patients and one recurrent glioma patient with clinical characteristics

Article Snippet: The sections were maintained with primary antibodies at 4°C throughout the night: TRAF7 (1:300, 11,780–1-AP, Proteintech, China), Ki67 (1:400, #9449, CST, USA), P53 (1:200, #2527, CST, USA), P21 (1:100, #2947, CST, USA), CCND1 (1:200, ab134175, Abcam, UK), CDK2 (1:100, ab32147, Abcam, UK).

Techniques: Derivative Assay, Expressing, Knockdown, Comparison, Migration, Control, Staining

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence

doi: 10.1186/s13046-025-03363-1

Figure Lengend Snippet: Sh-TRAF7 and Lomustine (CCNU) synergistically inhibit glioma tumor growth . A Schematic illustration of the experimental design for the glioma orthotopic implantation model, and evaluation of brain tumor growth after injection CCNU. B Bioluminescence images of nude mice bearing glioma orthotopic xenograft ( n = 5) were shown on days 14, 21, 28, 35, and 42. The nude mice were inoculated with U251 cells transfected with luciferase, divided into six groups: (1) Control, (2) Control + CCNU, (3) sh-TRAF7, (4) sh-TRAF7 + CCNU, (5) OE-TRAF7, (6) OE-TRAF7 + CCNU. The crossing in the blank area indicated that the corresponding mouse had died. C - D Survival curves of glioma-bearing mice, with median survival times listed in the accompanying table. E Quantitative analysis of bioluminescence. F The curves of body weight in nude mice

Article Snippet: The sections were maintained with primary antibodies at 4°C throughout the night: TRAF7 (1:300, 11,780–1-AP, Proteintech, China), Ki67 (1:400, #9449, CST, USA), P53 (1:200, #2527, CST, USA), P21 (1:100, #2947, CST, USA), CCND1 (1:200, ab134175, Abcam, UK), CDK2 (1:100, ab32147, Abcam, UK).

Techniques: Injection, Transfection, Luciferase, Control

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence

doi: 10.1186/s13046-025-03363-1

Figure Lengend Snippet: Histological analyses of TRAF7 inhibition and lomustine via mediating cellular senescence and G0/G1 arrest in vivo. A The whole brain of glioma nude mice were stained HE and TRAF7 (Full scan: scale bar = 2.5 mm; higher-magnification part below: scale bar = 100 µm). B Multiplex immunofluorescence staining image of cellular senescence markers (P21 and P53) and G0/G1 arrest markers (CCND1) and Ki67 in the tumor tissue. C IHC staining the cellular senescence markers (P21 and P53) and Ki67 in tumor tissue sections (scale bar = 100 µm)

Article Snippet: The sections were maintained with primary antibodies at 4°C throughout the night: TRAF7 (1:300, 11,780–1-AP, Proteintech, China), Ki67 (1:400, #9449, CST, USA), P53 (1:200, #2527, CST, USA), P21 (1:100, #2947, CST, USA), CCND1 (1:200, ab134175, Abcam, UK), CDK2 (1:100, ab32147, Abcam, UK).

Techniques: Inhibition, In Vivo, Staining, Multiplex Assay, Immunofluorescence, Immunohistochemistry

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence

doi: 10.1186/s13046-025-03363-1

Figure Lengend Snippet: A schematic mechanism overview of sh-TRAF7 and lomustine via mediating cellular senescence and G0/G1 arrest synergistic inhibit glioma tumor growth

Article Snippet: The sections were maintained with primary antibodies at 4°C throughout the night: TRAF7 (1:300, 11,780–1-AP, Proteintech, China), Ki67 (1:400, #9449, CST, USA), P53 (1:200, #2527, CST, USA), P21 (1:100, #2947, CST, USA), CCND1 (1:200, ab134175, Abcam, UK), CDK2 (1:100, ab32147, Abcam, UK).

Techniques: